Skip to main content

Delcath Systems Value Stock - Dividend - Research Selection

Delcath Systems

ISIN: US24661P5008, WKN: A2AP0C

Market price date: 30.11.-0001
Market price: 0,00 USD

Delcath Systems Fundamental data and company key figures of the share

Annual reports in USD
Key figures 29-12-2020
Cash flow
Net operating cash flow -23.690.000
Capital Expenditures -24.000
Free cash flow -23.714.000
Balance sheet
Total Equity -6.357.000
Liabilities & Shareholders equity 14.212.000
Income statement
Net income -8.879.000
Eps (diluted) -1.047,000
Diluted shares outstanding 25.900
Net sales/revenue 1.580.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization67.849,00 USD
Raw Data Source
Stock Split

Description of the company

Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,